Nirmatrelvir
A protease inhibitor that blocks the SARS-CoV-2 main protease, preventing the virus from processing the proteins needed for replication. It is used in combination with ritonavir (as Paxlovid) to treat mild-to-moderate COVID-19 in high-risk adults.
Peso Molecular
499,5000 g/mol
LogP
2,20
TPSA
131,00 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CC(C)(C)[C@H](NC(=O)C(F)(F)F)C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@H](C#N)C[C@@H]1CCNC1=O)C2(C)C
InChI
InChI=1S/C23H32F3N5O4/c1-21(2,3)16(30-20(35)23(24,25)26)19(34)31-10-13-14(22(13,4)5)15(31)18(33)29-12(9-27)8-11-6-7-28-17(11)32/h11-16H,6-8,10H2,1-5H3,(H,28,32)(H,29,33)(H,30,35)/t11-,12-,13-,14-,15-,16+/m0/s1
Molecular Formula
C23H32F3N5O4
HBD / HBA
3 / 8
Ligações Rotacionáveis
7
Átomos Pesados
35
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A protease inhibitor that blocks the SARS-CoV-2 main protease, preventing the virus from processing the proteins needed for replication. It is used in combination with ritonavir (as Paxlovid) to treat mild-to-moderate COVID-19 in high-risk adults.
Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.
Yes, Nirmatrelvir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4802135. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 155903259. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="nirmatrelvir"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/nirmatrelvir/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/nirmatrelvir/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/nirmatrelvir/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="nirmatrelvir"></drugfyi-drug>